Therapy resistance is a major problem in metastatic breast cancer and markers of importance for endocrine resistance (Akt2, FOXO, mTOR, Myc, PI3KCA, and PTEN) were investigated in patients with HR+ breast cancer. This evidence concerns the gene AKT2 and breast carcinoma.